BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang JL, Li YH, Wang LL, Liu HQ, Lu SY, Liu Y, Li K, Liu B, Li SY, Shao FM, Wang K, Sheng N, Li R, Cui JJ, Sun PC, Ma CX, Zhu B, Wang Z, Wan YH, Yu SS, Che Y, Wang CY, Wang C, Zhang Q, Zhao LM, Peng XZ, Cheng Z, Chang JB, Jiang JD. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther 2021;6:414. [PMID: 34873151 DOI: 10.1038/s41392-021-00835-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu J, Li H, Jia J, Huang Z, Liu S, Zheng Y, Mu S, Deng X, Zou X, Wang Y, Shang X, Cui D, Huang L, Feng X, Liu WJ, Cao B. Pandemic influenza A (H1N1) virus causes abortive infection of primary human T cells. Emerg Microbes Infect 2022;11:1191-204. [PMID: 35317717 DOI: 10.1080/22221751.2022.2056523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhu Q, Xu Y, Wang T, Xie F. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1053437] [Reference Citation Analysis]
3 Yu B, Chang J. The first Chinese oral anti-COVID-19 drug Azvudine launched. Innovation (Camb) 2022;3:100321. [PMID: 36106026 DOI: 10.1016/j.xinn.2022.100321] [Reference Citation Analysis]
4 Ji X, Meng X, Zhu X, He Q, Cui Y. Research and development of Chinese anti-COVID-19 drugs. Acta Pharm Sin B 2022. [PMID: 36119967 DOI: 10.1016/j.apsb.2022.09.002] [Reference Citation Analysis]
5 Ouyang J, Zaongo SD, Harypursat V, Li X, Routy J, Chen Y. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. Front Public Health 2022;10:945448. [DOI: 10.3389/fpubh.2022.945448] [Reference Citation Analysis]
6 Sun Z, Wu T, Xie H, Li Y, Zhang J, Su X, Qi H. The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. Vaccines (Basel) 2022;10:1103. [PMID: 35891267 DOI: 10.3390/vaccines10071103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yang Q, Jian X, Syed AAS, Fahira A, Zheng C, Zhu Z, Wang K, Zhang J, Wen Y, Li Z, Pan D, Lu T, Wang Z, Shi Y. Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants. Research (Wash D C) 2022;2022:9781758. [PMID: 35198984 DOI: 10.34133/2022/9781758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Chang J. 4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives. Acc Chem Res 2022;55:565-78. [PMID: 35077644 DOI: 10.1021/acs.accounts.1c00697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]